The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Cantor Fitzgerald on January 31, 2025. The analyst firm set a price target for $480.00 expecting VRTX to rise to within 12 months (a possible 3.54% upside). 76 analyst firms have reported ratings in the last year.

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Cantor Fitzgerald, and Vertex Pharmaceuticals reiterated their overweight rating.

The last upgrade for Vertex Pharmaceuticals Inc happened on December 9, 2024 when Jefferies raised their price target to $550. Jefferies previously had a hold for Vertex Pharmaceuticals Inc.

The last downgrade for Vertex Pharmaceuticals Inc happened on January 30, 2025 when Wells Fargo changed their price target from $460 to $460 for Vertex Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on January 31, 2025 so you should expect the next rating to be made available sometime around January 31, 2026.

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a reiterated with a price target of $480.00 to $480.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $463.58, which is out of the analyst’s predicted range.